SCHEMBL3490918

SCHEMBL3490918

CC(=O)Nc1sc(C(=O)OCc2ccccc2)c(C)c1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
TSHR P16473 2/20 0.59
MAPT P10636 3/20 0.54
KDM4E B2RXH2 3/20 0.54
GAA P10253 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
HK1 P19367 1/20 0.54
CYP2C19 P33261 1/20 0.54
HKDC1 Q2TB90 1/20 0.54
POLB P06746 3/20 0.54
HPGD P15428 2/20 0.52
RAB9A P51151 6/20 0.49
RXFP1 Q9HBX9 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8042616 0.88 ALDH1A1 (0.59) ALDH1A1TSHRMAPTKDM4EPOLB
SCHEMBL3493148 0.88 ALDH1A1 (0.56) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL8058314 0.87 ALDH1A1 (0.55) ALDH1A1TSHRMAPTKDM4ECYP1A2
SCHEMBL8055690 0.86 TRPM8 (0.51) ALDH1A1TSHRMAPTKDM4EPOLB
SCHEMBL13636678 0.84 RAB9A (0.48) ALDH1A1TSHRMAPTKDM4EPOLB
SCHEMBL6030484 0.84 MAPT (0.48) ALDH1A1TSHRMAPTCYP3A4POLB
SCHEMBL3494674 0.83 MAPT (0.47) ALDH1A1TSHRMAPTKDM4ECYP1A2
SCHEMBL6029449 0.82 MAPT (0.52) ALDH1A1TSHRMAPTPOLBHPGD
SCHEMBL6029258 0.80 MAPT (0.47) ALDH1A1TSHRMAPTKDM4ECYP3A4
SCHEMBL6030751 0.80 ALDH1A1 (0.57) ALDH1A1TSHRMAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140178503-A1 CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2014-06-26 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113418-A1 HETEROCYCLIC COMPOUND ACACA, ACAT1, CPT1B ALDH1A1 503/4885TSHR 3339/4885MAPT 3905/4885
US-20140178503-A1 CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS UTS2R, VDR, PTGDR ALDH1A1 2454/4885TSHR 48/4885MAPT 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.